Seoul National University Hospital to Support Domestic Promising Bio Companies in Growth and Overseas Expansion

2025-02-28

Seoul National University Hospital will begin supporting technology innovation and overseas expansion through the 'Global Bio Scale-up Company Development Project' (12.6 billion KRW, 8.74 million USD, over 6 years), a project to nurture promising domestic bio companies.

The 'Global Bio Scale-up Company Development Project' is a project supported by the Korea National Research Foundation to support the scaling up of promising biotechnologies and global expansion. This project is designed to discover domestic companies with promising technologies in the fields of new drugs/advanced bio and medical devices/digital healthcare, and support their entry into domestic and overseas markets through technology advancement and commercialization.

This project will be conducted in two phases: Phase 1 (2024-2026, 5.4 billion KRW, 3.75 million USD) and Phase 2 (2027-2029, 7.2 billion KRW, 5 million USD). Seoul National University Hospital will select at least 7 promising companies for each phase and provide support for ▲technology advancement ▲domestic and overseas business partnering ▲attracting domestic and overseas investment ▲legal consultation, etc.

In addition, Seoul National University Hospital plans to provide selected companies with opportunities to utilize the hospital's excellent clinical research infrastructure to support advanced R&D based on a medical big data research platform.

In the first phase of this project, three companies in the new drug/advanced bio field (Mediac, Illyme Therapeutics, and HyunTek EnBio) and four companies in the medical device/digital healthcare field (Microt, Soft & T, Emocog, and Connective) were selected.

Source: https://medifonews.com/news/article.html?no=199490